Marker Therapeutics Inc (MRKR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.51M
Last updated: Nov 17, 2026 at 11:06 AM ET
Marker Therapeutics Inc (MRKR) Stock Forecast
Analysts expect Marker Therapeutics (MRKR) to earn -$0.57 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.24M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 376.2%.
- Fiscal year ending Dec 31, 2026
- -$0.57
- EPS consensus, revenue $4.24M
- Fiscal year ending Dec 31, 2027
- -$0.53
- EPS consensus, revenue $20.19M
- Next report
- Mar 16, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.57 | -$0.63 to -$0.50 | 2 | $4.24M | $2.80M to $5.60M | 3 |
| Dec 31, 2027 | -$0.53 | -$0.89 to -$0.17 | 2 | $20.19M | $4.70M to $32.86M | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.31 to -$0.13 | 5 | $729637 | N/A | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.69.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.57 | -$0.57 | -$0.57 | -$0.57 | -$0.69 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.53 | -$0.53 | -$0.53 | -$0.53 | -$0.76 | N/A |
Frequently Asked Questions About MRKR
What is the MRKR stock forecast?
Consensus analyst estimates put Marker Therapeutics's EPS at -$0.57 for the fiscal year ending Dec 31, 2026, on revenue of $4.24M. The consensus rating from 3 analysts is Buy.
How do analysts rate MRKR stock?
Of 3 analysts covering Marker Therapeutics, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MRKR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.57, with estimates from -$0.63 to -$0.50 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.53, with estimates from -$0.89 to -$0.17 from 2 analysts.
What revenue do analysts expect from Marker Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.24M, with estimates from $2.80M to $5.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $20.19M, with estimates from $4.70M to $32.86M.
How many analysts cover MRKR?
3 analysts rate Marker Therapeutics stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MRKR pages: Overview, Earnings, Forecast, Financials, Competitors